99 related articles for article (PubMed ID: 26125142)
1. Protease inhibitors exposure is not related to lung cancer risk in HIV smoker patients: a nested case-control study.
Bruyand M; Le Marec F; Lavole A; Leffondre K; Spano JP; Le Moing V; Tattevin P; March L; Cadranel J; Bonnet F; Guiguet M
AIDS; 2015 Jun; 29(9):1105-9. PubMed ID: 26125142
[TBL] [Abstract][Full Text] [Related]
2. Influence of control selection in nested case-control studies: the example of exposure to antiretroviral treatment (ART) and the risk of myocardial infarction (MI) in the French Hospital Database on HIV (FHDH-ANRS CO4).
Guiguet M; Mary-Krause M; Ename B; Costagliola D; Grabar S
Pharmacoepidemiol Drug Saf; 2008 May; 17(5):468-74. PubMed ID: 18324608
[TBL] [Abstract][Full Text] [Related]
3. Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4.
Lang S; Mary-Krause M; Cotte L; Gilquin J; Partisani M; Simon A; Boccara F; Costagliola D;
Arch Intern Med; 2010 Jul; 170(14):1228-38. PubMed ID: 20660842
[TBL] [Abstract][Full Text] [Related]
4. Impact of Antiretroviral Drugs on Fracture Risk in HIV-Infected Individuals: A Case-Control Study Nested Within the French Hospital Database on HIV (FHDH-ANRS CO4).
Costagliola D; Potard V; Lang S; Abgrall S; Duvivier C; Fischer H; Joly V; Lacombe JM; Valantin MA; Mary-Krause M; Rozenberg S
J Acquir Immune Defic Syndr; 2019 Feb; 80(2):214-223. PubMed ID: 30422911
[TBL] [Abstract][Full Text] [Related]
5. Is the Risk of Myocardial Infarction in People With Human Immunodeficiency Virus (HIV) Associated With Atazanavir or Darunavir? A Nested Case-Control Study Within the French Hospital Database on HIV.
Costagliola D; Potard V; Lang S; de Castro N; Cotte L; Duval X; Duvivier C; Grabar S; Mary-Krause M; Partisani M; Ronot-Bregigeon S; Simon A; Tattevin P; Weiss L; Zucman D; Katlama C; Raffi F; Boccara F
J Infect Dis; 2020 Feb; 221(4):516-522. PubMed ID: 31828320
[TBL] [Abstract][Full Text] [Related]
6. Premature delivery in HIV-infected women starting protease inhibitor therapy during pregnancy: role of the ritonavir boost?
Sibiude J; Warszawski J; Tubiana R; Dollfus C; Faye A; Rouzioux C; Teglas JP; Ekoukou D; Blanche S; Mandelbrot L
Clin Infect Dis; 2012 May; 54(9):1348-60. PubMed ID: 22460969
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of ritonavir-boosted protease inhibitor monotherapy in the clinical setting: same results as in clinical trials? The PIMOCS Study Group.
Curran A; Monteiro P; Domingo P; Villar J; Imaz A; Martínez E; Fernández I; Knobel H; Podzamczer D; Iribarren JA; Peñaranda M; Crespo M;
J Antimicrob Chemother; 2014 May; 69(5):1390-6. PubMed ID: 24415645
[TBL] [Abstract][Full Text] [Related]
8. Effects of long-term exposure to traffic-related air pollution on respiratory and cardiovascular mortality in the Netherlands: the NLCS-AIR study.
Brunekreef B; Beelen R; Hoek G; Schouten L; Bausch-Goldbohm S; Fischer P; Armstrong B; Hughes E; Jerrett M; van den Brandt P
Res Rep Health Eff Inst; 2009 Mar; (139):5-71; discussion 73-89. PubMed ID: 19554969
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
Landman R; Capitant C; Descamps D; Chazallon C; Peytavin G; Katlama C; Pialoux G; Bentata M; Brun-Vézinet F; Aboulker JP; Yéni P;
J Antimicrob Chemother; 2009 Jul; 64(1):118-25. PubMed ID: 19420019
[TBL] [Abstract][Full Text] [Related]
10. Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study.
Martínez E; Larrousse M; Llibre JM; Gutiérrez F; Saumoy M; Antela A; Knobel H; Murillas J; Berenguer J; Pich J; Pérez I; Gatell JM;
AIDS; 2010 Jul; 24(11):1697-707. PubMed ID: 20467288
[TBL] [Abstract][Full Text] [Related]
11. Elevated incidence of lung cancer among HIV-infected individuals.
Engels EA; Brock MV; Chen J; Hooker CM; Gillison M; Moore RD
J Clin Oncol; 2006 Mar; 24(9):1383-8. PubMed ID: 16549832
[TBL] [Abstract][Full Text] [Related]
12. Pregnancy outcomes in women with HIV type-1 receiving a lopinavir/ritonavir-containing regimen.
Azria E; Moutafoff C; Schmitz T; Le Meaux JP; Krivine A; Pannier E; Firtion G; Compagnucci A; Finkielsztejn L; Taulera O; Tsatsaris V; Cabrol D; Launay O
Antivir Ther; 2009; 14(3):423-32. PubMed ID: 19474476
[TBL] [Abstract][Full Text] [Related]
13. Liver toxicity associated with antiretroviral therapy including efavirenz or ritonavir-boosted protease inhibitors in a cohort of HIV/hepatitis C virus co-infected patients.
Neukam K; Mira JA; Ruiz-Morales J; Rivero A; Collado A; Torres-Cornejo A; Merino D; de Los Santos-Gil I; Macías J; González-Serrano M; Camacho A; Parra-García G; Pineda JA;
J Antimicrob Chemother; 2011 Nov; 66(11):2605-14. PubMed ID: 21903660
[TBL] [Abstract][Full Text] [Related]
14. GSTM1 and CYP1A1 polymorphisms, tobacco, air pollution, and lung cancer: a study in rural Thailand.
Pisani P; Srivatanakul P; Randerson-Moor J; Vipasrinimit S; Lalitwongsa S; Unpunyo P; Bashir S; Bishop DT
Cancer Epidemiol Biomarkers Prev; 2006 Apr; 15(4):667-74. PubMed ID: 16614107
[TBL] [Abstract][Full Text] [Related]
15. Using ritonavir with indinavir in cases of virologic failure.
TreatmentUpdate; 2001; 12(12):7. PubMed ID: 11570095
[No Abstract] [Full Text] [Related]
16. Long-term response to highly active antiretroviral therapy with lopinavir/ritonavir in pre-treated vertically HIV-infected children.
Larrú B; Resino S; Bellón JM; de José MI; Fortuny C; Navarro ML; Gurbindo MD; Ramos JT; Soler Palacín P; Léon JA; Asensi M; Mellado MJ; Muñoz-Fernández MA
J Antimicrob Chemother; 2008 Jan; 61(1):183-90. PubMed ID: 18025025
[TBL] [Abstract][Full Text] [Related]
17. Lung cancer risk among female textile workers exposed to endotoxin.
Astrakianakis G; Seixas NS; Ray R; Camp JE; Gao DL; Feng Z; Li W; Wernli KJ; Fitzgibbons ED; Thomas DB; Checkoway H
J Natl Cancer Inst; 2007 Mar; 99(5):357-64. PubMed ID: 17341727
[TBL] [Abstract][Full Text] [Related]
18. Lopinavir/ritonavir or efavirenz plus two nucleoside analogues as first-line antiretroviral therapy: a non-randomized comparison.
De Luca A; Cozzi-Lepri A; Antinori A; Zaccarelli M; Bongiovanni M; Di Giambenedetto S; Marconi P; Cicconi P; Resta F; Grisorio B; Ciardi M; Cauda R; Monforte Ad; ; ; ;
Antivir Ther; 2006; 11(5):609-18. PubMed ID: 16964829
[TBL] [Abstract][Full Text] [Related]
19. HAART and lungs: do HIV protease inhibitors impact cancer risk?
Uldrick TS
AIDS; 2015 Jun; 29(9):1111-2. PubMed ID: 26125143
[No Abstract] [Full Text] [Related]
20. Risk factors for ritonavir intolerance and outcome after change to indinavir.
Casado JL; Perez-Elías MJ; Antela A; Martí-Belda P; de Lucas S; Muñoz V; Guerrero A
AIDS; 1998 Feb; 12(3):335-6. PubMed ID: 9580044
[No Abstract] [Full Text] [Related]
[Next] [New Search]
